This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

FV-100

ContraVir Pharmaceuticals, Inc.

Drug Names(s): FV100, CF-1743 prodrug

Description: FV-100 is an orally bioavailable nucleoside analogue, the pro-drug of a compound called CF-1743. This drug is a potent inhibitor of the varicella-zoster virus (VZV), which causes shingles. It is relativly specific for the virus because it is activated by the thymidine kinase (TK) and thymidylate kinase (dTMP-K) of VZV, but not related viruses. Inhibitex believes FV-100 will be dosed once-a-day.

Deal Structure: FV-100 was originally developed by FermaVir Pharmaceuticals.

Inhibitex received FV-100 as part of its acquisition of FermaVir Pharmaceuticals in 2007.

Bristol-Myers Squibb and Inhibitex
In January 2012, Bristol-Myers Squibb and Inhibitex announced that the companies signed a definitive agreement under which Bristol-Myers Squibb will acquire Inhibitex for $26.00 per share in cash pursuant to a cash tender offer and second step merger. The transaction, with an aggregate purchase price of approximately $2.5 billion, has been approved by the boards of directors of both companies. The board of directors of Inhibitex has agreed to recommend that Inhibitexs shareholders tender their shares in the tender offer. In addition, shareholders with beneficial ownership of approximately 17% of Inhibitexs common stock have entered into agreements with Bristol-Myers Squibb to support the transaction and to tender their shares in the tender offer.

Under the terms of the...See full deal structure in Biomedtracker


FV-100 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug